Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
Phase 2/3
150
about 9 months
40–85
1 site in IL
About this study
Researchers are testing whether alternative therapies, such as metformin alone or with rapamycin and low-dose naltrexone, can help maintain weight loss after stopping GLP-1 medications. The trial will compare different groups of participants who either use these alternatives or do not to see if they experience less weight regain over six months post-cessation compared to those without any alternative medication.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Metformin
- 2.Take Naltrexone
- 3.Take Rapamycin
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
metformin (Biguanide antidiabetic; reduces liver glucose production and improves insulin sensitivity), naltrexone, sirolimus, ascorbic acid (vit C)
oral, injection, intramuscular
Secondary: Evaluate the effectiveness of metformin + LDN on mood-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + LDN on physical health-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + LDN on tolerability of treatment in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + rapamycin on mood-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + rapamycin on physical health-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin + rapamycin on tolerability of treatment in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin on mood-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent), Evaluate the effectiveness of metformin on physical health-related quality of life in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)